x
|
ANNUAL REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
|
For the fiscal year ended
December 31, 2008
|
||
OR
|
||
o
|
TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
|
For the transition period
from to
|
Delaware
|
11-3516358
|
|
(State
or other jurisdiction of incorporation or
organization)
|
(I.R.S.
Employer Identification
No.)
|
|
9620
Medical Center Drive
Rockville,
Maryland
|
20850
|
|
(Address of principal
executive offices)
|
(Zip
Code)
|
Title of Each
Class
|
Name of Each Exchange on Which
Registered
|
|
Common Stock, $.0001 par
value per share
|
NYSE
Alternext US
|
Large
accelerated filer o
|
Accelerated
filer x
|
Non-accelerated
filer o
|
Smaller
reporting company x
|
(Do
not check if a smaller reporting company)
|
Class
|
Outstanding at March 16,
2009
|
|
Common
Stock, $.0001 par value per share
|
56,025,649 shares
|
|
Document
|
Parts Into Which
Incorporated
|
|
None.
|
-
|
REXAHN
PHARMACEUTICALS, INC.
|
||||
Date:
March 24, 2009
|
By:
|
/s/
Tae Heum Jeong
|
||
Tae
Heum Jeong
|
||||
Chief
Financial Officer
|
Name
|
Title
|
/s/ Chang H. Ahn*
Chang
H. Ahn
|
Chairman
and Chief Executive Officer
|
/s/ Tae Heum Jeong*
Tae
Heum Jeong
|
Chief
Financial Officer, Secretary and Director
|
/s/ Freddie Ann
Hoffman*
Freddie
Ann Hoffman
|
Director
|
/s/ David McIntosh*
David
McIntosh
|
Director
|
/s/ Charles Beever*
Charles
Beever
|
Director
|
/s/ Kwang Soo Cheong*
Kwang
Soo Cheong
|
Director
|
/s/ Y. Michele
Kang*
Y.
Michele Kang
|
Director
|
Exhibit
|
||
Number
|
Description
of Exhibit
|
|
|
||
Consent
of Parente Randolph, LLC
|
||
Consent
of Lazar, Levine & Felix LLP
|
||
24
|
Power
of Attorney filed as Exhibit 24 to the Company’s Annual Report on Form
10-K filed on March 16, 2009 is hereby incorporated by
reference.
|
|
Certification
of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under
the Securities Exchange Act of 1934, as amended.
|
||
Certification
of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under
the Securities Exchange Act of 1934, as
amended.
|